Avadel Pharmaceuticals delivered a robust performance in the second quarter of 2025, with LUMRYZ net revenue increasing by 64% year-over-year to $68.1 million. The company achieved a net income of $9.7 million and an EPS of $0.10, marking its first profitable quarter since the launch of LUMRYZ. Patient numbers for LUMRYZ also saw substantial growth, reaching 3,100 patients. The company raised its full-year 2025 revenue guidance to $265 - $275 million, reflecting strong commercial execution and market position.

Avadel Pharmaceuticals plc announced robust financial results for the first quarter ended March 31, 2025, with net product revenue from LUMRYZ sales reaching $52.5 million, a 93% increase year-over-year. The company added 300 patients on LUMRYZ during the quarter, bringing the total to 2,800. Following a favorable Federal Circuit decision, Avadel is now able to pursue FDA approval for LUMRYZ in Idiopathic Hypersomnia (IH) and other indications. The company also raised its full-year 2025 guidance for net product revenue and cash flow.

Avadel Pharmaceuticals delivered significant revenue growth in Q4 2024, driven by strong sales of LUMRYZ. The company reported a 158% increase in quarterly revenue compared to the previous year, reaching $50.4 million. While net losses improved year-over-year, the company remains focused on expanding patient access and driving market penetration.

Avadel Pharmaceuticals reported $50.0 million in net product revenue for the third quarter 2024, driven by sales of LUMRYZ. The company also received FDA approval for LUMRYZ for pediatric narcolepsy and saw a court uphold the FDA's determination that LUMRYZ is clinically superior to twice-nightly oxybate products. They had 2,300 patients on LUMRYZ as of September 30th, including 700 patients that initiated therapy in the quarter.

Avadel Pharmaceuticals reported $41.5 million in net product revenue from LUMRYZ sales in Q2 2024, a significant increase from $1.5 million in the same period last year. The company is also advancing its clinical trials for LUMRYZ in idiopathic hypersomnia and preparing for a potential FDA approval for pediatric narcolepsy.

Avadel Pharmaceuticals reported $27.2 million in net product revenue from LUMRYZ sales in Q1 2024. The company is focused on expanding the market for LUMRYZ and advancing its pipeline, including a Phase 3 trial in idiopathic hypersomnia.

Avadel Pharmaceuticals reported $19.5 million in net product revenue for the fourth quarter of 2023 from sales of LUMRYZ. R&D expenses were $2.4 million, and SG&A expenses were $41.3 million. The net loss for the quarter was $28.8 million, or ($0.32) per diluted share. Cash, cash equivalents, and marketable securities were $105.1 million as of December 31, 2023.

Avadel Pharmaceuticals reported $7.0 million in net product revenue for the third quarter of 2023, driven by LUMRYZ sales. The company also highlighted the submission of an sNDA for LUMRYZ in the pediatric narcolepsy population and the addition of LUMRYZ to preferred position for CVS commercial formularies effective January 1, 2024.

Avadel Pharmaceuticals reported $1.5 million in net product revenues for Q2 2023, driven by the U.S. commercial launch of LUMRYZ, which began on June 5, 2023. The company's net loss for the quarter was $64.4 million, or ($0.83) per diluted share. As of June 30, 2023, cash, cash equivalents and marketable securities totaled $160.5 million.

Avadel Pharmaceuticals announced FDA approval for LUMRYZ and reported first quarter 2023 financial results. The company secured over $200 million of capital to support the launch of LUMRYZ.

Avadel Pharmaceuticals reported a net loss of $27.5 million for the fourth quarter of 2022. The company is preparing for the potential commercial launch of LUMRYZ and secured $200 million in capital to support the launch.

Avadel Pharmaceuticals reported its Q3 2022 financial results with a net loss of $20.1 million. The company is preparing for the commercial launch of LUMRYZ, expected no later than Q3 2023, and is working to potentially accelerate its final approval. Cash, cash equivalents and marketable securities were $106.5 million as of September 30, 2022.

Avadel Pharmaceuticals reported a net loss of $63.4 million for the second quarter of 2022. The company received tentative approval for LUMRYZ from the FDA and is advancing activities to accelerate final approval. They have extended their cash runway to the final FDA decision.

Avadel Pharmaceuticals reported a net loss of $26.4 million, or ($0.45) per diluted share, for the quarter ended March 31, 2022. The company's cash, cash equivalents, and marketable securities were $123.5 million as of March 31, 2022. The company continues to work with the FDA to complete the review of its NDA for FT218.

Avadel Pharmaceuticals reported a net loss of $22.3 million for the fourth quarter of 2021. The company is focused on the FDA review for FT218 and preparing for its potential commercial launch.

Avadel Pharmaceuticals reported a net loss of $22.0 million for the third quarter ended September 30, 2021. The company continues to advance its commercial team and payor discussions in anticipation of a potential FT218 launch.

Avadel Pharmaceuticals reported no revenue for Q2 2021 due to the sale of sterile injectable products in June 2020. R&D expenses increased to $6.8 million, and SG&A expenses rose to $15.2 million. The company had a net loss of $19.6 million, or ($0.33) per diluted share. Cash, cash equivalents, and marketable securities totaled $202.8 million as of June 30, 2021.

Avadel Pharmaceuticals reported its Q1 2021 financial results with no revenue due to the sale of its sterile injectable products. The company's net loss increased to $13.4 million, or ($0.23) per diluted share. The company is focused on the development and potential launch of FT218.

Avadel Pharmaceuticals reported no revenue for Q4 2020 due to the sale of sterile injectable products. R&D expenses decreased, while SG&A expenses increased. The company reported a net loss of $11.3 million, or ($0.19) per diluted share. Cash, cash equivalents, and marketable securities totaled $221.4 million as of December 31, 2020.

Avadel Pharmaceuticals reported no revenue for Q3 2020 due to the sale of sterile injectable products. R&D expenses were $5.6 million, and SG&A expenses were $8.4 million. The net loss for the quarter was $11.7 million, or ($0.20) per diluted share. Cash, cash equivalents, and marketable securities were $231.6 million as of September 30, 2020.

Avadel Pharmaceuticals reported second quarter results with a focus on the development of FT218. They completed a public equity offering for $125.0 million and sold their legacy portfolio for $42.0 million. Net income for the quarter was $30.9 million, or $0.49 per diluted share.

Avadel Pharmaceuticals reported first quarter 2020 financial results, with revenues of $12.2 million compared to $16.4 million in the first quarter of 2019. The company's net loss for the quarter was $0.9 million, or $0.02 per share, compared to a net loss of $13.0 million, or $0.35 per share, for the same period in 2019.

Avadel Pharmaceuticals reported fourth-quarter revenues of $11.0 million, a decrease compared to $20.9 million in the fourth quarter of 2018. The net loss for the quarter was $2.7 million, or $0.07 per share, compared to a net loss of $63.9 million, or $1.72 per share, for the same period in 2018. The company's cash, cash equivalents, and marketable securities totaled $64.2 million as of December 31, 2019.